Kathy Oubre Shares Her Take on How the US Biosimilar Market Is Maturing
Kathy Oubre, MS, chief executive officer of Pontchartrain Cancer Center, explains the progress she has seen regarding biosimilar utilization and acceptance.
Kathy Oubre, MS, chief executive officer of Pontchartrain Cancer Center, explains the progress she has seen regarding biosimilar utilization and acceptance.
Transcript
What sort of gains have you seen for biosimilars over the course of the past year and where do you see this going in 2022?
Oubre: Our biosimilar market in the US remains in its infancy, but it is growing. And if you review the bodies of literature out there, NCCN [National Comprehensive Cancer Network] did a poster presentation early in 2021 that showed that for the therapeutic agents, they saw the most rapid adoption of the Herceptin [trastuzumab] biosimilars out of all of the biosimilars to date. And it was for patients who were on treatment or new to treatment. It showed this massive increase in access to care, and i also showed a cost savings to practices in patients. And then we continue to see those types of anecdotal evidence, or hard evidence, shown in that NCCN poster presentation. you know, Ronny Gal with Bernstein did an analysis in 2021. Again, narrowing that same thing: that biosimilars are playing a large role in helping to bring down and stabilize health care costs and increase access to care.
The COA [Community Oncology Alliance] biosimilars data are showing that same thing. It's 122 community oncology practices across the US and 2.4 million administrations. That's a lot of covered lives. And so, the US market is in its infancy, but it's really showing progress and maturity. And if you also then look at what it's doing with ASP [average sales prices] and Medicare allowables, it's doing its part in helping to bring down health care costs, without sacrificing quality.
I think we need to continue to believe in the biosimilars market and do what we can in working with our payers and our members of Congress and CMS to foster a healthy biosimilars market.
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
Study: Biosimilar Use, Dose Rounding Produce More Cost Savings Than Either Strategy Alone
November 18th 2023A retrospective study of New England patients receiving trastuzumab or bevacizumab found that combining dose rounding and biosimilar use resulted in greater cost savings than either strategy alone.
Dr Fran Gregory Sizes Up the US Adalimumab Market: Will Biosimilars See Success?
September 17th 2023On this episode of Not So Different, Fran Gregory, PharmD, MBA, vice president of emerging therapies at Cardinal Health, analyzes the adalimumab market so far in the United States and provides insight into how the market needs to adapt to accept these products and ensure lower drug costs for patients.
Panelists Deliberate Strategies to Enhance Biosimilar Integration in Managed Care Spaces
November 13th 2023At the recent Academy of Managed Care Pharmacy Nexus meeting, panelists discussed the impact of introducing biosimilars in new medical fields, emphasizing the need for more education and collaboration to ensure their smooth integration into health care systems.
Public Payer in Poland Saves €243 Million by Using Biosimilar TNF Inhibitors
November 11th 2023The use of biosimilars of tumor necrosis factor (TNF) inhibitors within Poland’s public payer saved over €243 million from 2013 to 2021, with about 68% of that coming from the rheumatic musculoskeletal diseases alone.
